New drug to fight eczema

Dupilumab, approved for use here recently, has been shown to be effective, but is costly

A newly approved first-of-its-kind biologic drug may give hope to patients who are having a hard time bringing their moderate to severe atopic eczema under control.

Some patients at both public and private institutions, including adolescents, have been treated with the newly available Dupilumab, sold under the brand name Dupixent, which has been shown to be relatively safe and effective in international trials that included Singapore. The Health Sciences Authority approved its use in adult patients about two months ago.

Please or to continue reading the full article. Learn more about ST PREMIUM.

Enjoy unlimited access to ST's best work

  • Exclusive stories and features on multiple devices
  • In-depth analyses and opinion pieces
  • ePaper and award-winning multimedia content
A version of this article appeared in the print edition of The Straits Times on July 01, 2019, with the headline 'New drug to fight eczema'. Print Edition | Subscribe